The California Institute for Regenerative Medicine has done a good job overall but should make several changes to enhance its viability, credibility, and operations, says a new report.1

California voters approved the creation of the institute and authorized a $3bn (£1.9bn; €2.3bn) bond issue in 2004 to fund stem cell research. The purpose was to assure the state’s leadership in the emerging field by promoting research, jobs, and, ultimately, stem cell based treatments. It inspired a handful of other states to fund other research activities.

The institute commissioned the report into its work and governance, which was conducted by the Institute of Medicine and released on 6 December.

Harold …